Zobrazeno 1 - 10
of 285
pro vyhledávání: '"Nicholas J, Sarlis"'
Autor:
Beryl L. Manning-Geist, Sacha Gnjatic, Carol Aghajanian, Jason Konner, Sarah H. Kim, Debra Sarasohn, Krysten Soldan, William P. Tew, Nicholas J. Sarlis, Dmitriy Zamarin, Sara Kravetz, Ilaria Laface, Teresa Rasalan-Ho, Jingjing Qi, Phillip Wong, Paul J. Sabbatini, Roisin E. O’Cearbhaill
Publikováno v:
Cancers; Volume 15; Issue 5; Pages: 1458
We examined the safety and immunogenicity of sequential administration of a tetravalent, non-HLA (human leukocyte antigen) restricted, heteroclitic Wilms’ Tumor 1 (WT1) peptide vaccine (galinpepimut-S) with anti–PD-1 (programmed cell death protei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a4f790e9fa7f2f19d3171a97c1f294a
Autor:
Alessandro M. Vannucchi, Hagop M. Kantarjian, Jean-Jacques Kiladjian, Jason Gotlib, Francisco Cervantes, Ruben A. Mesa, Nicholas J. Sarlis, Wei Peng, Victor Sandor, Prashanth Gopalakrishna, Abdel Hmissi, Viktoriya Stalbovskaya, Vikas Gupta, Claire Harrison, Srdan Verstovsek
Publikováno v:
Haematologica, Vol 100, Iss 9 (2015)
Ruxolitinib, a potent Janus kinase 1/2 inhibitor, resulted in rapid and durable improvements in splenomegaly and disease-related symptoms in the 2 phase III COMFORT studies. In addition, ruxolitinib was associated with prolonged survival compared wit
Externí odkaz:
https://doaj.org/article/bc698fc1152a4379840e4851a3e4dbc4
Autor:
Laura Katz, Maria E. Arcila, Joseph G. Jurcic, Jae H. Park, Dan Douer, Nicholas J. Sarlis, David A. Scheinberg, Martin S. Tallman, Suzanne Chanel, Rong Zhang, Peter Maslak, Todd L. Rosenblat, Tao Dao, Renier J. Brentjens, Raajit K. Rampal, Mark G. Frattini, Yvette Bernal
Publikováno v:
Blood advances. 2(3)
A National Cancer Institute consensus study on prioritization of cancer antigens ranked the Wilms tumor 1 (WT1) protein as the top immunotherapy target in cancer. We previously reported a pilot study of a multivalent WT1 peptide vaccine (galinpepimut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e23d280a7dd416c0f8ae90f407a647a
https://pubmed.ncbi.nlm.nih.gov/29386195
https://pubmed.ncbi.nlm.nih.gov/29386195
Autor:
James A. Kaye, Debanjali Mitra, Kelly Reith, Lance T Piecoro, Nicholas J. Sarlis, Tariq I. Mughal, Jennifer Brown
Publikováno v:
Cancer Medicine
Myelofibrosis (MF) is a clonal hematopoietic malignancy characterized by constitutional and localized symptoms, progressive splenomegaly, bone marrow fibrosis, and cytopenias. Although MF is well studied, few studies exist regarding its symptomatic b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d17a6d9ce8e0f334ad46001689224fea
https://doi.org/10.1002/cam4.136
https://doi.org/10.1002/cam4.136
Autor:
Richard S. Levy, William Sun, Ruben A. Mesa, Srdan Verstovsek, Alan L. Shields, Thomas Hare, Susan Erickson-Viitanen, Victor Sandor, Nicholas J. Sarlis
Publikováno v:
Leukemia Research. 37:911-916
Patient-reported outcomes (PROs) and spleen size in patients not receiving therapy (N=154) in COMFORT-I, a randomized, double-blind study of the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis were evaluated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6dd4264e55b5babbf57764cf98b6975
https://doi.org/10.1016/j.leukres.2013.04.017
https://doi.org/10.1016/j.leukres.2013.04.017
Autor:
Joseph I. Clark, Jonathan J. Beitler, Douglas Adkins, Guilherme Rabinowits, Anne O'Neill, Robert I. Haddad, Sarah Riley, Marshall R. Posner, Sewanti Limaye, Roy B. Tishler, Fadlo R. Khuri, Jochen H. Lorch, Nicholas J. Sarlis
Publikováno v:
The Lancet Oncology. 14:257-264
Summary Background The relative efficacy of the addition of induction chemotherapy to chemoradiotherapy compared with chemoradiotherapy alone for patients with head and neck cancer is unclear. The PARADIGM study is a multicentre open-label phase 3 st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df4d81e598787e7b40608eb98f5c7f9b
https://doi.org/10.1016/s1470-2045(13)70011-1
https://doi.org/10.1016/s1470-2045(13)70011-1
Autor:
Kristen Concialdi, Shreekant Parasuraman, Nicholas J. Sarlis, Ahmad Naim, Kelly Reith, Marco DiBonaventura
Publikováno v:
Experimental Hematology & Oncology
Background Hydroxyurea (HU) is among the most commonly used cytoreductive treatments for polycythemia vera (PV), but previous research and clinical experience suggest that not all patients respond optimally, consistently, or durably to HU treatment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d9bc0e51e9719b8a5800924de2175ba
http://europepmc.org/articles/PMC4736254
http://europepmc.org/articles/PMC4736254
Publikováno v:
Expert Opinion on Pharmacotherapy. 13:2397-2407
Myelofibrosis (MF) is a debilitating hematologic malignancy characterized by progressive splenomegaly, burdensome symptoms, cytopenias and shortened survival. Chronic alterations in Janus-associated kinase-signal transducer and activator of transcrip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2da5ea32c56d1ca800190eab7dedf0f6
https://doi.org/10.1517/14656566.2012.732998
https://doi.org/10.1517/14656566.2012.732998
Autor:
Nicholas J. Sarlis, Qingyi Wei, Guojun Li, Liliana Mugartegui, Erich M. Sturgis, Mark Zafereo, Li Xu
Publikováno v:
Molecular Carcinogenesis. 51:E158-E167
The insulin-like growth factor (IGF) pathway is believed to play a pivotal role in thyroid carcinogenesis. Polymorphisms of IGF-1 and IGF binding protein-3 (IGFBP-3) have been associated with modulation of risk for the emergence of assorted common ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::106ef5bc9aec87b505c3c487a7be031e
https://doi.org/10.1002/mc.21900
https://doi.org/10.1002/mc.21900
Autor:
Sham Mailankody, Alexander M. Lesokhin, Landau Heather, Sean M. Devlin, Neha Korde, David J. Chung, Hani Hassoun, Ola Landgren, Sergio Giralt, Nikoletta Lendvai, Nicholas J. Sarlis, Guenther Koehne
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 17:S343-S344
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dfd363e08c433b5554a648db468bb55c
https://doi.org/10.1016/j.clml.2017.07.164
https://doi.org/10.1016/j.clml.2017.07.164